KRT14 and inflammatory bowel disease: The capability to modulate key inflammatory components by therapies aiming to control the activity of different cell types, such as macrophages, besides reducing the production of cytokines and NO, such as that observed in our study when NFJ was used, represents a promising approach to constrain the progression of inflammation in IBD.